Cargando…
Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial
BACKGROUND: This trial aimed to compare the outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres(®) microspheres (CSM) and conventional transarterial chemoembolization cTACE in the treatment of patients with unresectable hepatocellular carcinoma (HCC). PATIENTS...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039469/ https://www.ncbi.nlm.nih.gov/pubmed/36794998 http://dx.doi.org/10.2478/raon-2023-0001 |
_version_ | 1784912274382651392 |
---|---|
author | Shi, Zhongxing Wang, Dongqing Kang, Tanrong Yi, Ru Cui, Liming Jiang, Huijie |
author_facet | Shi, Zhongxing Wang, Dongqing Kang, Tanrong Yi, Ru Cui, Liming Jiang, Huijie |
author_sort | Shi, Zhongxing |
collection | PubMed |
description | BACKGROUND: This trial aimed to compare the outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres(®) microspheres (CSM) and conventional transarterial chemoembolization cTACE in the treatment of patients with unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: A total of 90 patients were divided into DEB-TACE group (n = 45) and cTACE group (n = 45). The treatment response, overall survival (OS), progression-free survival (PFS), and the safety were compared between the two groups. RESULTS: The objective response rate (ORR) in the DEB-TACE group was significantly higher than that in cTACE group at 1, 3, and 6 months of follow-up (P = 0.031, P = 0.003, P = 0.002). The complete response (CR) in DEB-TACE group was significantly higher than that in cTACE group at 3 months (P = 0.036). Survival analysis revealed that, DEB-TACE group had better survival benefits than cTACE group (median OS: 534 days vs. 367 days, P = 0.027; median PFS: 352 days vs. 278 days P = 0.004). The degree of liver function injury was more serious in DEB-TACE group at 1 week, but was similar between the two groups at 1 month. DEB-TACE with CSM caused a high incidence of fever and a severe abdominal pain (P = 0.031, P = 0.037). CONCLUSIONS: DEB-TACE with CSM showed better treatment response and survival benefits than cTACE group. Although a transient more severe liver damage, high incidence of fever and a severe abdominal pain occurred in the DEB-TACE group, it could be resolved through symptomatic treatment. |
format | Online Article Text |
id | pubmed-10039469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-100394692023-03-26 Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial Shi, Zhongxing Wang, Dongqing Kang, Tanrong Yi, Ru Cui, Liming Jiang, Huijie Radiol Oncol Research Article BACKGROUND: This trial aimed to compare the outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres(®) microspheres (CSM) and conventional transarterial chemoembolization cTACE in the treatment of patients with unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: A total of 90 patients were divided into DEB-TACE group (n = 45) and cTACE group (n = 45). The treatment response, overall survival (OS), progression-free survival (PFS), and the safety were compared between the two groups. RESULTS: The objective response rate (ORR) in the DEB-TACE group was significantly higher than that in cTACE group at 1, 3, and 6 months of follow-up (P = 0.031, P = 0.003, P = 0.002). The complete response (CR) in DEB-TACE group was significantly higher than that in cTACE group at 3 months (P = 0.036). Survival analysis revealed that, DEB-TACE group had better survival benefits than cTACE group (median OS: 534 days vs. 367 days, P = 0.027; median PFS: 352 days vs. 278 days P = 0.004). The degree of liver function injury was more serious in DEB-TACE group at 1 week, but was similar between the two groups at 1 month. DEB-TACE with CSM caused a high incidence of fever and a severe abdominal pain (P = 0.031, P = 0.037). CONCLUSIONS: DEB-TACE with CSM showed better treatment response and survival benefits than cTACE group. Although a transient more severe liver damage, high incidence of fever and a severe abdominal pain occurred in the DEB-TACE group, it could be resolved through symptomatic treatment. Sciendo 2023-02-17 /pmc/articles/PMC10039469/ /pubmed/36794998 http://dx.doi.org/10.2478/raon-2023-0001 Text en © 2023 Zhongxing Shi, Dongqing Wang, Tanrong Kang, Ru Yi, Liming Cui, Huijie Jiang, published by Sciendo https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
spellingShingle | Research Article Shi, Zhongxing Wang, Dongqing Kang, Tanrong Yi, Ru Cui, Liming Jiang, Huijie Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial |
title | Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial |
title_full | Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial |
title_fullStr | Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial |
title_full_unstemmed | Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial |
title_short | Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial |
title_sort | comparison of callispheres(®) microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039469/ https://www.ncbi.nlm.nih.gov/pubmed/36794998 http://dx.doi.org/10.2478/raon-2023-0001 |
work_keys_str_mv | AT shizhongxing comparisonofcallispheresmicrospheresdrugelutingbeadsandconventionaltransarterialchemoembolizationinhepatocellularcarcinomapatientsarandomizedcontrolledtrial AT wangdongqing comparisonofcallispheresmicrospheresdrugelutingbeadsandconventionaltransarterialchemoembolizationinhepatocellularcarcinomapatientsarandomizedcontrolledtrial AT kangtanrong comparisonofcallispheresmicrospheresdrugelutingbeadsandconventionaltransarterialchemoembolizationinhepatocellularcarcinomapatientsarandomizedcontrolledtrial AT yiru comparisonofcallispheresmicrospheresdrugelutingbeadsandconventionaltransarterialchemoembolizationinhepatocellularcarcinomapatientsarandomizedcontrolledtrial AT cuiliming comparisonofcallispheresmicrospheresdrugelutingbeadsandconventionaltransarterialchemoembolizationinhepatocellularcarcinomapatientsarandomizedcontrolledtrial AT jianghuijie comparisonofcallispheresmicrospheresdrugelutingbeadsandconventionaltransarterialchemoembolizationinhepatocellularcarcinomapatientsarandomizedcontrolledtrial |